The UK government has finalised a controversial medicines agreement with the United States, which it heralds as a significant victory for British interests. Under the terms of the deal, British pharmaceutical exports to the US will be exempt from punitive tariffs proposed by the Trump administration. Simultaneously, the agreement facilitates greater patient access to potentially life-extending treatments within the UK by relaxing NHS spending constraints.
Government Hails Economic and Health Benefits
In an official announcement released on Thursday, ministers emphasised the dual advantages of the pact. They described it as "a win for British patients, British businesses and the British economy." The government argues that protecting approximately £5 billion worth of annual drug exports from tariffs of up to 100% will safeguard around 50,000 jobs in the UK pharmaceutical sector. Furthermore, it is anticipated to stimulate increased investment in research, development, and manufacturing within the country.
Enhanced Access to Treatments
A key component of the deal involves modifying the cost-effectiveness thresholds used by the National Institute for Health and Care Excellence (Nice). The annual limit the NHS can pay for a treatment to extend and improve a patient's life has been raised from £30,000 to £35,000. This adjustment has already led to the approval of two new cancer drugs this week, which the government cites as evidence of the agreement delivering tangible benefits for seriously ill patients.
Mounting Criticism and Financial Concerns
Despite the government's optimistic portrayal, the deal has encountered fierce opposition from political rivals, health campaigners, and independent experts. The Liberal Democrats, alongside the campaign group Global Justice Now, have voiced profound scepticism, accusing the government of capitulating to US and pharmaceutical industry pressures at the NHS's expense.
Questionable Financial Logic
Dr Andrew Hill, a prominent drugs expert at the University of Liverpool, has projected that the UK's commitment to double its spending on newly developed medicines—from 0.3% to 0.6% of GDP by 2035—will incur an annual cost of approximately £9 billion by that date. He starkly contrasts this figure with the £5 billion in annual drug exports the deal aims to protect.
"Why spend an extra £9bn a year on higher drug prices to protect drug exports to the US of only £5bn a year? The maths simply does not add up," Dr Hill stated. He further suggested that redirecting such funds towards expanding existing NHS services could save more lives.
Political Backlash and Secrecy Allegations
Helen Morgan, the Liberal Democrat health spokesperson, condemned the agreement, urging the government to resist external pressure. "Starmer must stand strong against the bully in the White House, and protect our health service as a matter of urgency," she asserted.
Critics have also lambasted the lack of transparency and parliamentary oversight. The final deal was disclosed via a press release after 5 PM on Thursday, with the full text promised only later that evening. This has raised alarms about hidden details and costs, especially given that concerns have simmered since the deal's outline emerged last December.
Tim Bierley of Global Justice Now criticised the process, saying, "It has made this agreement without consulting parliament, confirmed it via press release with no full text, then snuck it out at the start of the Easter weekend." The Liberal Democrats have demanded that MPs be granted the opportunity to scrutinise and vote on the agreement.
Implications for Future Drug Approvals
The initial two drugs approved under the new pricing framework target specific cancers: one reduces the progression risk of a gene-related brain tumour by 50%, and the other serves as a last-resort treatment for a rare stomach cancer. With the revised thresholds, Nice now faces increased pressure to approve other medications previously rejected on cost-effectiveness grounds, such as the breast cancer drug Enhertu.
While the government champions the deal for its potential to boost the economy and enhance patient care, the controversy underscores a deep-seated tension between international trade interests and the sustainable funding of the UK's cherished National Health Service. The full ramifications of this UK-US partnership will likely unfold in the coming years, amid ongoing debates over healthcare financing and sovereignty.
